EP0724578A1 - Amine derivatives as calcium channel antagonists - Google Patents

Amine derivatives as calcium channel antagonists

Info

Publication number
EP0724578A1
EP0724578A1 EP94929536A EP94929536A EP0724578A1 EP 0724578 A1 EP0724578 A1 EP 0724578A1 EP 94929536 A EP94929536 A EP 94929536A EP 94929536 A EP94929536 A EP 94929536A EP 0724578 A1 EP0724578 A1 EP 0724578A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
alk
propyl
galkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94929536A
Other languages
German (de)
French (fr)
Inventor
David Gwyn Cooper
Ronald Joseph King
Thomas Henry Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0724578A1 publication Critical patent/EP0724578A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Definitions

  • the present invention relates to amine derivatives, more particularly aryloxy-, arylthio-, and aroyl-alkylamino compounds having a heteroatom in the alkyl portion, to processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the treatment of ischaemic stroke.
  • Stroke is reportedly the third most common cause of death in the developed world.
  • Current therapies for ischaemic stroke are limited and have a number of disadvantages, such as the risk of exacerbating haemorrhage. There is therefore a need for new and improved treatments for ischaemic stroke.
  • British Patent No. 924961 describes, as intermediates for the preparation of anti- nematodal agents, compounds of formula R. W .CH2.CH2.NXY, wherein R is phenyl optionally substituted by inter alia halogen, alkyl or alkoxy, X and Y are inter alia alkyl, or NXY represents a pyrrolidino, piperidino or morpholino group and W is a straight saturated chain containing up to 16 carbon atoms and 1 to 3 non-adjacent oxygen atoms.
  • the present invention therefore provides, in a first aspect, a compound of formula
  • R.1 and R ⁇ each independently represent: hydrogen, C ⁇ galkyl, C3_gcycloalkyl, C3_gcycloalkylC _4alkyl, arylC ⁇ alkyl, C2-6hydroxyalkyl or R3R 4 NC2-6_lkyl (where R ⁇ and R 4 independently represent H or C ⁇ _4alkyl) or NR--R represents a saturated heterocyclic ring containing 4 to 9 ring members, one of which may optionally be a further heteroatom selected from O, S or NR* ⁇ (where
  • R5 is H, C ⁇ alkyl or arylC1.4a.kyl), which ring may optionally be substituted by one or two substituents selected from Cj.galkyl and C ⁇ alkoxy;
  • X represents O, S or NR6 (where R ⁇ is hydrogen, C1.4a._kyl or arylC1.4a._kyl);
  • n is 2 to 5
  • m is 1 to 5 (providing that when m is 1, Y represents a bond)
  • Ar represents phenyl optionally substituted by 1-3 substituents selected from halo, Ci.galkyl, Ci.galkoxy, C ⁇ _2alkylenedioxy e.g.
  • Y 1 is Y 2 (CH2) r where r is 0 or 1 and Y 2 is O, S or NR where R? is hydrogen or C ⁇ _4_lkyl, Z is (CH2.
  • S or -CH CH-, s is 0, 1 or 2 or Ar is the corresponding tricyclic dehydro ring system; or a pharmaceutically acceptable salt thereof for use as a therapeutic agent.
  • the invention provides the use of a compound of formula (I) as hereinbefore defined or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of conditions where a calcium antagonist is required.
  • Compounds of formula (I) and their pharmaceutically acceptable salts are preferably used in the manufacture of a medicament for the treatment of conditions related to the accumulation of calcium in the brain cells of mammals.
  • n and m preferably are independently from 2 to 4 such that the total of n + m is from 4 to 8.
  • n + m is preferably 7 and when Y is other than a bond n + m is preferably 6.
  • Y preferably represents oxygen.
  • X preferably represents oxygen or NR -*; R6 preferably represents hydrogen.
  • Alk* and Alk 2 preferably independently represent CH2 or when branched, HXCH ) or C(CH3>2.
  • A is oxygen q is preferably zero and p is preferably zero or 1.
  • p + q is preferably 1 or 2.
  • p and q are preferably both zero.
  • tricyclic heteroaryl groups examples include dibenzofuranyl, dibenzothienyl, carbazole, N-methylcarbazole, acridine and dibenzoxepine.
  • the tricyclic moiety can be linked to the remainder of formula (I) via any suitable ring atom.
  • Suitable substituents for Ph, and tricyclic heteroaryl groups include, for example, 1 to 3 substituents selected from halogen, trifluoromethyl, trifluoromethoxy, C1.4a.kyl
  • Ar is phenyl mono-substituted by phenoxy, benzyl, benzyloxy, benzoyl, halobenzoyl or halo; phenyl disubstituted by halo; or Ar is 2-dibenzofuranyl.
  • Ar is phenyl substituted by benzyl, benzoyl, fluorobenzoyl or benzyloxy.
  • the substituent is preferably at the 3- or 4- position of the phenyl ring.
  • Ci.galkyl groups present in the compounds of formula (I), alone or as part of another group, can be straight or branched.
  • a Ci.galkyl group may be for example methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl or any branched isomer thereof such as isopropyl, t-butyl, or sec-pentyl.
  • a salt of a compound (I) should be pharmaceutically acceptable.
  • pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, methanesulphonate or similar pharmaceutically acceptable inorganic or organic acid addition salts.
  • Other non- pharmaceutically acceptable salts may be used for example in the isolation of a final product and are included within the scope of this invention.
  • the compounds of formula (I) may contain one or more asymmetric centres. Such compounds will exist as optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two are included within the scope of the invention. Further, all diastereomeric forms possible (pure enantiomers and mixtures thereof) are within the scope of the invention. Certain compounds of formula (I) are believed to be novel. Thus, in a further aspect the invention provides novel compounds of formula (IA):
  • A represents -CH2CH2-;
  • reduction of a compound wherein A and/or Y represent C O to a compound wherein A and/or Y represent -CH2-; followed if desired by salt formation.
  • the reaction between a compound of formula (II) and a compound of formula (HI) can be carried out under standard conditions.
  • the leaving group L 1 may be for example a halogen atom or a sulphonyloxy group eg. methane- sulphonyloxy or p-toluene sulphonyloxy.
  • reaction may be effected in the absence or presence of solvent such as dimethylformamide or methylethylketone optionally in the presence of a base such as sodium hydride or potassium carbonate and at a temperature in the range 0 to 200°C.
  • solvent such as dimethylformamide or methylethylketone
  • a base such as sodium hydride or potassium carbonate
  • the reaction is carried out in the presence of diethyl azodicarboxylate and triphenyl phosphine.
  • This reaction may optionally be effected in the presence of a solvent such as tetrahydrofuran.
  • the reaction of a compound of formula (IV) with a compound of formula (V) according to process (b) may be effected in conventional manner, for example using excess amine as solvent or alternatively using an organic solvent, such as ethanol or dimethylformamide.
  • the leaving group L 2 may be for example a halide such as bromide or chloride, an acyloxy group such as acetoxy or chloroacetoxy or a sulphonyloxy group such as methanesulphonyloxy or p-toluenesulphonyloxy.
  • the reaction may be carried out in the presence of a base such as potassium carbonate, sodium hydride or potassium t- butoxide or an excess of amine may be employed.
  • reductive amination of an aldehyde (X) may be effected using a reducing agent such as sodium cyanoborohydride in the presence of a compound of formula (V), according to procedures well known in the art. It will be appreciated that when X represents NH the nitrogen atom should preferably be protected for example as described below.
  • reaction of compounds (XI) and (XII) may be effected in an analogous manner to process (a) described above.
  • Reduction of a pyridinium derivative (XIII) according to process (0 may be effected for example by hydrogenation, using a noble metal catalyst such as palladium on charcoal, platinum or platinum oxide (Adam's catalyst), suitably in a solvent such as an alcohol e.g. ethanol.
  • L 2 may be halogen or a sulphonic acid residue such as a tosylate or mesylate and the reaction may be carried out under standard conditions in a solvent such as dimethylformamide, optionally in the presence of a base eg sodium hydride.
  • a base eg sodium hydride.
  • L 2 should be fluoro, such that the compound (XV) is a fluoro- substituted aryl compound, and the reaction is preferably effected in the presence of a strong base such as sodium hydride, and in a polar organic solvent such as dimethylsulphoxide or dimethylformamide.
  • Interconversion reactions according to process (h) may be carried out using standard methods.
  • a compound of formula (II) can be prepared under standard alkylation conditions by reacting a compound of formula (XVI) :
  • L and L 2 are preferably selected so that the compound of formula (V) reacts selectively with L 2 .
  • L is suitably hydroxy and L 2 is suitably halo.
  • Compounds of formula (HI) are commercially available or may be prepared using standard procedures well known in the art, for example using methods analogous to those described for process (a).
  • a compound of formula (IV) may be prepared by Friedel-Craft acylation of a compound HAr with an acylating agent of the formula L 2 (CH2) n X(CH2) m C(O)Hal, where Hal represents a halogen atom such as bromo or chloro. It will be appreciated that when X represents NH, nitrogen protection should preferably be employed. The carbonyl group in the resulting compound of formula (IV) may if desired subsequently be reduced.
  • Compounds of formula (V) and (XVI) are commercially available or may be prepared by standard methods. Compounds of formula (VI) may be prepared according to general processes (a) and (b) described herein employing an appropriate amide corresponding to formula (II) or (V).
  • Compounds of formula (VTI) may be prepared by acylation of a compound of formula (V) for example with an appropriate acid chloride or ester, which may itself be prepared from a compound of formula (III) by reaction with an appropriate, commercially available bromoalkyl ester or acid, followed if necessary or desired by conversion to an acid chloride.
  • a compound (VII) may be prepared by a method analogous to process (a).
  • Amides of formulae (VHI) and (IX) may be prepared for example by reaction of a corresponding carboxylic acid or an activated derivative thereof such as an acid halide, ester or anhydride, with an amine of formula ArY(CH2) m (R ⁇ ) H or R 1 R 2 N(CH 2 ) n (R 6 )NH respectively.
  • An aldehyde of formula (X) may be prepared for example by reduction of the corresponding nitrile using a reducing agent such as diisobutyl aluminium hydride, in the presence of an inert solvent such as toluene. Conveniently reductive amination of the aldehyde is carried out in situ, i.e. the compound of formula (I) is obtained from the nitrile in a one-pot reaction without isolation of the intermediate aldehyde.
  • the nitrile may itself be prepared by reacting a compound of formula (IV) wherein L 2 is halo with potassium cyanide.
  • Compounds (X) may also be prepared by other standard procedures such as reduction of an ester or oxidation of an alcohol.
  • Compounds of formula (XI) may be prepared by methods analogous to any of processes (a) - (d) described herein. Alternatively a compound (XI) may be obtained by catalytic hydrogenation of a corresponding compound of formula (I) wherein Ar represents a benzyloxyphenyl group. This therefore provides a further method of converting a compound of formula (I) to a different compound of formula (I).
  • Suitable protecting groups include aralkyl groups such as benzyl, diphenylmethyl or triphenylmethyl and acyl groups such as acetyl, trifluoroacetyl, benzoyl, methoxycarbonyl, ethoxycarbonyl, t- butoxycarbonyl or benzyloxycarbonyl.
  • An aralkyl group such as benzyl may be cleaved by hydrogenolysis, and an acyl group such as benzoyl may be cleaved by hydrolysis.
  • a compound of formula (I) When a compound of formula (I) is obtained as a mixture of enantiomers, these may be separated by conventional methods such as crystallisation in the presence of a resolving agent, or chromatography, for example using a chiral HPLC column.
  • the invention also encompasses any novel intermediates described herein, in particular those of formulae (II), (IV), (VI), (VII), (V ⁇ l), (IX) and (XII).
  • Compounds of the invention have been found to exhibit high calcium influx blocking activity, for example in neurons.
  • the compounds are expected to be of use in therapy in treating conditions and diseases related to an accumulation of calcium in the brain cells of mammals, in particular humans.
  • the compounds are expected to be of use in the treatment of anoxia, ischaemia including for example stroke, migraine, visceral pain, epilepsy, traumatic head or spinal injury, AIDS -related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal.
  • the invention also provides a method of treatment of conditions or diseases related to (e.g. caused or exacerbated by) the accumulation of calcium in the brain cells of mammals which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) as hereinbefore defined or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treatment of anoxia, ischaemia including for example stroke, migraine, visceral pain, epilepsy, traumatic head or spinal injury, AIDS -related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal, which comprises administering to a subject in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the compounds of the present invention are usually administered in a standard pharmaceutical composition.
  • the present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound of formula (I) as hereinbefore defined or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
  • the compounds of the invention may be administered by any convenient method for example by oral, parenteral, buccal, rectal or transdermal administration and the pharmaceuucal compositions adapted accordingly. Parenteral administration is generally preferred.
  • the compounds of formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
  • a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • Compounds of the invention may also be administered parenterally, by bolus injection or continuous infusion.
  • Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
  • Both liquid and solid compositions may contain other excipients known in the pharmaceutical art, such as a cyclodextrin or a solubilising agent e.g. cremophore.
  • a cyclodextrin or a solubilising agent e.g. cremophore.
  • the composition is in unit dose form such as a tablet, capsule or ampoule.
  • Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 60 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, eg. 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of between 0J mg and 100 mg, preferably between 0J mg and 60 mg, eg. 1 to 40 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
  • the compounds of the invention may be administered by continuous intravenous infusion, preferably at a dose of up to 400 mg per day.
  • the total daily dosage by oral administration could be in the range 1 to 2000 mg and the total daily dosage by parenteral administration could be in the range OJ to 400 mg.
  • the compounds may be administered for a period of continuous therapy, for example for a week or more.
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered in combination or concurrently with one or more other therapeutic agents, for example a thrombolytic agent such as anistreplase, streptokinase or a tissue plasminogen activator; an excitatory amino acid antagonist such as an NMDA antagonists; a free radical inhibitor; or a calpain inhibitor.
  • a thrombolytic agent such as anistreplase, streptokinase or a tissue plasminogen activator
  • an excitatory amino acid antagonist such as an NMDA antagonists
  • a free radical inhibitor such as an NMDA antagonists
  • the pipette (internal solution) contained in mM: CsCl, 130; HEPES, 10; EGTA, 10; MgCl2, 4; ATP, 2; buffered to pH 7.2 with CsOH.
  • Cells were bathed in a normal Tyrodes solution before establishment of whole cell recording when the bathing solution was changed to one allowing isolation of Ca 2+ currents.
  • the external solution for recording Ca 2+ channel currents contained in mM: BaCl2, 10; TEA-C1, 130; glucose, 10; HEPES, 10; MgCl2, 1; buffered to pH 7.3 with TEA-OH. Barium was used as the charge carrier as this assists in current isolation and calcium dependent inactivation of current is avoided.
  • Peak voltage gated Ca 2+ channel currents of up to 10 nA from dorsal root ganglion neurons were recorded using 10 mM Ba 2+ as charge carrier. Currents were evoked from a holding potential of -80 mV to a test potential of 0 or +10 mV every 15 seconds. This test potential was at the peak of the current voltage relationship and assessing block at this point reduced any errors due to drifting holding potential. Some cells showed slow rundown of current as is commonly seen when recording Ca 2+ currents. The rundown rate was measured in control conditions and extrapolated through the time of drug application to derive a rundown corrected control value.
  • Block by 20 ⁇ M drug was assessed 3 minutes after drug application.
  • Buffer Suitable buffers include citrate, phosphate, sodium hydroxide/hydrochloric acid.
  • Solvent Typically water but may also include cyclodextrins (1-100 mg) and co-solvents such as propylene glycol, polyethylene glycol and alcohol.
  • Diluent e.g. Microcrystalline cellulose, lactose, starch Binder : e.g. Polyvinylpyrrolidone, hydroxypropymethylcellulose
  • Disintegrant e.g. Sodium starch glycollate, crospovidone Lubricant : e.g. Magnesium stearate, sodium stearyl fumarate. Oral Suspension
  • Suspending agent e.g. Xanthan gum, microcrystalline cellulose
  • Diluent e.g. sorbitol solution, typically water
  • Preservative e.g. sodium benzoate
  • Buffer e.g. citrate
  • Co-solvent e.g. alcohol, propylene glycol, polyethylene glycol, cyclodextrin
  • Preparation 7 3-(4-Benzylphenoxy)propylamine hydrochloride
  • the product from Preparation 6 (7.5g), hydrazine hydrate (7.5ml) and ethanol (250ml) were heated at reflux until all the solid had dissolved and heating was continued for a further 30 minutes.
  • the cooled mixture was filtered and the filtrate was evaporated.
  • the residue was dissolved in hot ethanol (150ml) and treated with concentrated hydrochloric acid (10ml). The resulting solution was allowed to cool and the precipitate was collected to give the title compound as a white solid which was used without further purification.
  • N-[3-(3,4-Dichlorophenoxy)propyl]-N-[3-(l-piperidino)propyl]amine dihydrochloride A mixture of 3-(3,4-dichlorphenoxy)propylamine (2.2g), 80% sodium hydride (0.6g), 1- (3-chloropropyl)piperidine hydrochloride (1.98g) and dimethylformamide (30ml) was stirred under nitrogen at 60°C for 36 hours. The mixture was treated with water and extracted with ether. The ether layer was washed with dilute sodium hydroxide solution and brine, dried over sodium sulphate and the solvent removed.
  • N- ⁇ 3-[4-(4-Fluorobenzoyl)phenoxy]propyl ⁇ -N-[3-(l-piperidino)propyl]amine dihydrochloride A mixture 1-piperidinopropylamine (0.426g), 80% sodium hydride (0.072g), and dimethylformamide (10ml) was stirred under argon at 40°C for 0.5hours. The resulting solution was treated with 4-(3-bromopropyloxy)-4'-fluorobenzophenone (l.Og) and then stirred under argon at 60°C for 18 hours.

Abstract

Compounds of formula (I), wherein R?1 and R2¿ each independently represent: hydrogen, C¿1-8?alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-4alkyl, arylC1-4alkyl, C2-6hydroxyalkyl or R?3R4NC¿2-6alkyl (where R?3 and R4¿ independently represent H or C¿1-4?alkyl) or NR?1R2¿ represents a saturated heterocyclic ring containing 4 to 9 ring members, one of which may optionally be a further heteroatom selected from O, S or NR5, (where R5 is H, C¿1-4?alkyl or arylC1-4alkyl), which ring may optionally be substituted by one or two substituents selected from C1-6alkyl and C1-6alkoxy; X represents O, S or NR?6¿ (where R6 is hydrogen, C¿1-4?alkyl or arylC1-4alkyl); Y represents O, S, C=O or a bond; n is 2 to 5; m is 1 to 5 (providing that when m is 1, Y represents a bond); and Ar represents phenyl optionally substituted by 1-3 substituents selected from halo, C1-8alkyl, C1-8alkoxy, C1-2alkylenedioxy e.g. methylenedioxy, trifluoromethyl, trifluoromethyloxy, or by a group Ph(Alk?1)¿pA(Alk2)q- where Ph isoptionally substituted phenyl, A is a bond, O, S, -C=O or CH=CH, Alk1 and Alk2 independently represent C¿1-4?alkyl which may be straight or branched and p and q are independently 0 or 1, provided that the length of -(Alk?1)¿pA(Alk2)q- does not exceed 5 atoms, or Ar is an optionally substitued tricyclic heteroaryl group (a) in which Y?1 is Y2(CH¿2)r where r is 0 or 1 and Y2 is O, S or NR7 where R7 is hydrogen or C¿1-4?alkyl, Z is (CH2)s or -CH=CH-, s is 0, 1 or 2 or Ar is the corresponding tricyclic dehydro ring system; and pharmaceutically acceptable salts thereof are useful as atherapeutic agents, e.g. for the treatment of ischaemic stroke.

Description

amine derivatives as calcium channel antagonists
The present invention relates to amine derivatives, more particularly aryloxy-, arylthio-, and aroyl-alkylamino compounds having a heteroatom in the alkyl portion, to processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the treatment of ischaemic stroke.
Stroke is reportedly the third most common cause of death in the developed world. Current therapies for ischaemic stroke are limited and have a number of disadvantages, such as the risk of exacerbating haemorrhage. There is therefore a need for new and improved treatments for ischaemic stroke.
British Patent No. 924961 describes, as intermediates for the preparation of anti- nematodal agents, compounds of formula R. W .CH2.CH2.NXY, wherein R is phenyl optionally substituted by inter alia halogen, alkyl or alkoxy, X and Y are inter alia alkyl, or NXY represents a pyrrolidino, piperidino or morpholino group and W is a straight saturated chain containing up to 16 carbon atoms and 1 to 3 non-adjacent oxygen atoms.
We have now found that certain amine derivatives exhibit activity as calcium channel antagonists.
The present invention therefore provides, in a first aspect, a compound of formula
(I) :
1
\
N-(CH2)nX(CH2)rnYAr R
Formula (I) wherein
R.1 and R^ each independently represent: hydrogen, Cμgalkyl, C3_gcycloalkyl, C3_gcycloalkylC _4alkyl, arylC^alkyl, C2-6hydroxyalkyl or R3R4NC2-6_lkyl (where R^ and R4 independently represent H or C \ _4alkyl) or NR--R represents a saturated heterocyclic ring containing 4 to 9 ring members, one of which may optionally be a further heteroatom selected from O, S or NR*\ (where
R5 is H, C^alkyl or arylC1.4a.kyl), which ring may optionally be substituted by one or two substituents selected from Cj.galkyl and C^alkoxy;
X represents O, S or NR6 (where R^ is hydrogen, C1.4a._kyl or arylC1.4a._kyl);
Y represents O, S, C=O or a bond; n is 2 to 5; m is 1 to 5 (providing that when m is 1, Y represents a bond); and Ar represents phenyl optionally substituted by 1-3 substituents selected from halo, Ci.galkyl, Ci.galkoxy, Cι_2alkylenedioxy e.g. methylenedioxy, trifluoromethyl, trifluoromethyloxy, or by a group Ph(Alkl)pA(Alk2)q- where Ph is optionally substituted phenyl, A is a bond, O, S, -C=O or CH=CH, Alk1 and Alk2 independently represent Cι_4_lkyl which may be straight or branched and p and q are independently 0 or 1 , provided that the length of (Alkl)A(Alk2) does not exceed 5 atoms, or Ar is an optionally substituted tricyclic heteroaryl group:
in which Y1 is Y2(CH2)r where r is 0 or 1 and Y2 is O, S or NR where R? is hydrogen or C ι_4_lkyl, Z is (CH2.S or -CH=CH-, s is 0, 1 or 2 or Ar is the corresponding tricyclic dehydro ring system; or a pharmaceutically acceptable salt thereof for use as a therapeutic agent.
In a further aspect the invention provides the use of a compound of formula (I) as hereinbefore defined or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of conditions where a calcium antagonist is required. Compounds of formula (I) and their pharmaceutically acceptable salts are preferably used in the manufacture of a medicament for the treatment of conditions related to the accumulation of calcium in the brain cells of mammals.
In compounds of formula (I), n and m preferably are independently from 2 to 4 such that the total of n + m is from 4 to 8. When Y is a bond, n + m is preferably 7 and when Y is other than a bond n + m is preferably 6. Y preferably represents oxygen.
X preferably represents oxygen or NR -*; R6 preferably represents hydrogen. When Ar is substituted by a group Ph(Alk-JpA(Alk2)q-, A is preferably oxygen, C=O or a bond. Alk* and Alk2 preferably independently represent CH2 or when branched, HXCH ) or C(CH3>2. When A is oxygen q is preferably zero and p is preferably zero or 1. When A is a bond the sum of p + q is preferably 1 or 2. When A represents CH=CH or C=O, p and q are preferably both zero.
Examples of tricyclic heteroaryl groups include dibenzofuranyl, dibenzothienyl, carbazole, N-methylcarbazole, acridine and dibenzoxepine. The tricyclic moiety can be linked to the remainder of formula (I) via any suitable ring atom.
Suitable substituents for Ph, and tricyclic heteroaryl groups include, for example, 1 to 3 substituents selected from halogen, trifluoromethyl, trifluoromethoxy, C1.4a.kyl Preferably Ar is phenyl mono-substituted by phenoxy, benzyl, benzyloxy, benzoyl, halobenzoyl or halo; phenyl disubstituted by halo; or Ar is 2-dibenzofuranyl. Most preferably Ar is phenyl substituted by benzyl, benzoyl, fluorobenzoyl or benzyloxy. The substituent is preferably at the 3- or 4- position of the phenyl ring.
Alkyl groups present in the compounds of formula (I), alone or as part of another group, can be straight or branched. Thus, a Ci.galkyl group may be for example methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl or any branched isomer thereof such as isopropyl, t-butyl, or sec-pentyl.
It will be appreciated that for use in medicine a salt of a compound (I) should be pharmaceutically acceptable. Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, methanesulphonate or similar pharmaceutically acceptable inorganic or organic acid addition salts. Other non- pharmaceutically acceptable salts may be used for example in the isolation of a final product and are included within the scope of this invention.
It will be appreciated that the compounds of formula (I) may contain one or more asymmetric centres. Such compounds will exist as optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two are included within the scope of the invention. Further, all diastereomeric forms possible (pure enantiomers and mixtures thereof) are within the scope of the invention. Certain compounds of formula (I) are believed to be novel. Thus, in a further aspect the invention provides novel compounds of formula (IA):
1a
N-(CH2)nXa -2)mYaAra R2β
Formula (IA) wherein n and m are as defined for formula (I) and R a, R2a, Xa, Ya and Ara are as defined for Rl, R2, X, Y, and Ar; with the proviso that when Xa represents O, Ya represents O or a bond, and Rla and R2a represent C .galkyl or NRlaR a represents pyrrolidino, piperidino or morpholino then Ara does not represent phenyl substituted by halogen, alkyl or alkoxy; and salts thereof.
Particular compounds of the invention, which are believed to be novel compounds include:
N-[3-(4-benzyloxyphenoxy)propyl]-N-[3-(l-piperidino)propyl]amine, 1- { 3-[3-(4-benzyloxyphenoxy)propyloxy]propyl } piperidine, N-[3-(3,4-dichlorophenoxy)propyl]-N-[3-(l-piperidino)propyl]amine,
N-[3-(4-benzylphenoxy)propyl]-N-[3-(l-piperidino)propyl]amine,
N-{3-[4-(4-fluorobenzoyl)phenoxy]propyl}-N-[3-(l-piperidino)propyl]amine, and pharmaceutically acceptable salts thereof. The compounds of the present invention can be prepared by processes analogous to those known in the art. The present invention therefore provides in a further aspect, a process for the preparation of a novel compound of formula (I) which comprises:
(a) to prepare a compound wherein X represents O, S or NR^ or Y represents O or S, reaction of a compound of formula (II):
1
R
\
N(CH2)n[X(CH2)m]xL R
Formula (II) in which R , R2, X, n and m are as defined in formula (I), x is zero or 1 and L is a group displaceable with a nucleophile with a compound of formula (III) :
H[X(CH2)m]yYAr Formula (HI) in which Ar, X and m are as defined in formula (I), Y represents O or S and y represents zero or 1 such that the sum of x + y = 1;
(b) reaction of a compound of formula (IV) :
L2(CH2)nX(CH2)mYAr Formula (IV) in which Ar, X, Y, m and n are as defined for formula (I),and L2 is a leaving group, with a compound of formula (V) :
Formula (V) in which R-- and R2 are as defined in formula (I); or
(c) reduction of an amide of formula (VI), (VII), (Vπi) or (IX) :
Formula (VI)
- A -
Formula (VII)
Formula (VHI)
Formula (IX)
O wherein R , R2, X, Y, Ar, n and m are as defined above and R c is a group reducible to d) Reductive animation of an aldehyde of formula (X) :
OHC-(CH2)n-iX(CH2)mYAr
Formula (X) wherein Ar, X, Y, n and m are as hereinbefore defined, in the presence of a compound of formula (V) as defined above. e) To prepare a compound wherein Ar represents phenyl substituted by
Ph(Alk-*)pO-, alkylation of a compound of formula (XI) :
Formula (XI) wherein R1, R2, X, Y, n and m are as hereinbefore defined; with an alkylating agent of formula (XII) :
P Alk^pL1 Formula (XII) wherein Ph, Alk1, p and L are as hereinbefore defined. f) To prepare a compound where R--R2N- represents an optionally substituted piperidine ring, reduction of a pyridine derivative of formula (XHI) :
A- Formula (XIII) wherein Ar, X, Y, n and m are as hereinbefore defined, R^ represents hydrogen or an optional substituent as hereinbefore defined and A" is a counter anion; g) to prepare a compound wherein X represents O, S or NR6 or Y represents O or S, reaction of a compound of formula (XIV) :
Formula (XIV) wherein R1, R2, X, n and m are as defined in formual (I), Y is O or S and x is zero or 1; with a compound of formula (XV) : [(CH2)mY]yAr Formula (XV) wherein Ar, m and L2 are as hereinbefore defined, Y is O or S and y is zero or 1 such that the sum of x + y = 1; h) Interconversion of one compound of formula (I) to a different compound of formula (I) e.g. (i) reduction of a compound wherein A represents CH=CH to a compound wherein
A represents -CH2CH2-; (ii) reduction of a compound wherein A and/or Y represent C=O to a compound wherein A and/or Y represent -CH2-; followed if desired by salt formation. In process (a) the reaction between a compound of formula (II) and a compound of formula (HI) can be carried out under standard conditions. For example the leaving group L1 may be for example a halogen atom or a sulphonyloxy group eg. methane- sulphonyloxy or p-toluene sulphonyloxy. In this case the reaction may be effected in the absence or presence of solvent such as dimethylformamide or methylethylketone optionally in the presence of a base such as sodium hydride or potassium carbonate and at a temperature in the range 0 to 200°C. Alternatively when L1 is hydroxy and y is zero, the reaction is carried out in the presence of diethyl azodicarboxylate and triphenyl phosphine.
Such a reaction is known as the Mitsunobu reaction (as described in Synthesis 1981, 1).
This reaction may optionally be effected in the presence of a solvent such as tetrahydrofuran.
The reaction of a compound of formula (IV) with a compound of formula (V) according to process (b) may be effected in conventional manner, for example using excess amine as solvent or alternatively using an organic solvent, such as ethanol or dimethylformamide. The leaving group L2 may be for example a halide such as bromide or chloride, an acyloxy group such as acetoxy or chloroacetoxy or a sulphonyloxy group such as methanesulphonyloxy or p-toluenesulphonyloxy. The reaction may be carried out in the presence of a base such as potassium carbonate, sodium hydride or potassium t- butoxide or an excess of amine may be employed.
Reduction of an amide of formula (VI), (VII), (VIII) or (IX) according to process (c) may be effected using a suitable reducing agent such as lithium aluminium hydride. It will be appreciated that in this process Y or A will not generally be C=O, unless simultaneous reduction of the group Y and/or A is desired.
In process (d) reductive amination of an aldehyde (X) may be effected using a reducing agent such as sodium cyanoborohydride in the presence of a compound of formula (V), according to procedures well known in the art. It will be appreciated that when X represents NH the nitrogen atom should preferably be protected for example as described below.
In process (e) the reaction of compounds (XI) and (XII) may be effected in an analogous manner to process (a) described above. Reduction of a pyridinium derivative (XIII) according to process (0 may be effected for example by hydrogenation, using a noble metal catalyst such as palladium on charcoal, platinum or platinum oxide (Adam's catalyst), suitably in a solvent such as an alcohol e.g. ethanol.
In process (g) the reaction between compounds of formula (XIV) and (XV) can take place under conditions which depend on the nature of the group L2 and the value of y.
For example, when y is 1, L2 may be halogen or a sulphonic acid residue such as a tosylate or mesylate and the reaction may be carried out under standard conditions in a solvent such as dimethylformamide, optionally in the presence of a base eg sodium hydride. When y is zero, L2 should be fluoro, such that the compound (XV) is a fluoro- substituted aryl compound, and the reaction is preferably effected in the presence of a strong base such as sodium hydride, and in a polar organic solvent such as dimethylsulphoxide or dimethylformamide. Interconversion reactions according to process (h) may be carried out using standard methods. Thus for example conversion of a compound (I) wherein A represents -CH=CH- into a compound (I) wherein A represents -CH2CH2- may be effected by catalytic hydrogenation and reduction of a compound where Y and/or A represents C=O may be effected using a suitable reducing agent such as lithium aluminium hydride.
A compound of formula (II) can be prepared under standard alkylation conditions by reacting a compound of formula (XVI) :
L2-(CH2)n[X(CH2)m]x-L1
Formula (XVI) in which L * L2, X, m, n and x are as hereinbefore defined, with a compound of formula (V) as hereinbefore defined. The reaction is suitably carried out under analogous conditions to those described above for process (b). It will be appreciated that where X is NH the nitrogen group should be protected, for example as described below.
It will be appreciated that in compounds of formula (XVI) the leaving groups L and L2 are preferably selected so that the compound of formula (V) reacts selectively with L2. For example, in a compound of formula (XVI) L is suitably hydroxy and L2 is suitably halo. Compounds of formula (HI) are commercially available or may be prepared using standard procedures well known in the art, for example using methods analogous to those described for process (a).
Compounds of formula (IV) can be prepared by reacting a compound of formula (HI) as hereinbefore defined with a compound of formula (XVI) as hereinbefore defined. In this reaction both L and L2 can be identical, for example halo, but it will be appreciated that in this case n and m should also have the same values. The reaction is suitably carried out in the presence of a weak base such as potassium carbonate. Alternatively the reaction may be carried out under phase transfer conditions using a strong base such as potassium hydroxide. Alternatively where Y represents C=O a compound of formula (IV) may be prepared by Friedel-Craft acylation of a compound HAr with an acylating agent of the formula L2(CH2)nX(CH2)mC(O)Hal, where Hal represents a halogen atom such as bromo or chloro. It will be appreciated that when X represents NH, nitrogen protection should preferably be employed. The carbonyl group in the resulting compound of formula (IV) may if desired subsequently be reduced. Compounds of formula (V) and (XVI) are commercially available or may be prepared by standard methods. Compounds of formula (VI) may be prepared according to general processes (a) and (b) described herein employing an appropriate amide corresponding to formula (II) or (V).
Compounds of formula (VTI) may be prepared by acylation of a compound of formula (V) for example with an appropriate acid chloride or ester, which may itself be prepared from a compound of formula (III) by reaction with an appropriate, commercially available bromoalkyl ester or acid, followed if necessary or desired by conversion to an acid chloride. Alternatively a compound (VII) may be prepared by a method analogous to process (a). Amides of formulae (VHI) and (IX) may be prepared for example by reaction of a corresponding carboxylic acid or an activated derivative thereof such as an acid halide, ester or anhydride, with an amine of formula ArY(CH2)m (R^) H or R1R2N(CH2)n(R6)NH respectively.
An aldehyde of formula (X) may be prepared for example by reduction of the corresponding nitrile using a reducing agent such as diisobutyl aluminium hydride, in the presence of an inert solvent such as toluene. Conveniently reductive amination of the aldehyde is carried out in situ, i.e. the compound of formula (I) is obtained from the nitrile in a one-pot reaction without isolation of the intermediate aldehyde. The nitrile may itself be prepared by reacting a compound of formula (IV) wherein L2 is halo with potassium cyanide. Compounds (X) may also be prepared by other standard procedures such as reduction of an ester or oxidation of an alcohol.
Compounds of formula (XI) may be prepared by methods analogous to any of processes (a) - (d) described herein. Alternatively a compound (XI) may be obtained by catalytic hydrogenation of a corresponding compound of formula (I) wherein Ar represents a benzyloxyphenyl group. This therefore provides a further method of converting a compound of formula (I) to a different compound of formula (I).
Compounds of formula (XII) are commercially available or are known in the literature.
Compounds of formula (XIII) may be prepared in a similar manner to process (b) above employing an optionally substituted pyridine as the amine.
Compounds of formula (XIV) may be prepared as described for formula (II) above.
It will be appreciated that during certain of the above processes (a) to (h) as well as during the preparation of intermediates it may be necessary to protect any unsubstituted nitrogen atoms present in the molecule, with for example an N-protecting group, which may subsequently removed by methods well known in the art. Suitable protecting groups include aralkyl groups such as benzyl, diphenylmethyl or triphenylmethyl and acyl groups such as acetyl, trifluoroacetyl, benzoyl, methoxycarbonyl, ethoxycarbonyl, t- butoxycarbonyl or benzyloxycarbonyl. An aralkyl group such as benzyl may be cleaved by hydrogenolysis, and an acyl group such as benzoyl may be cleaved by hydrolysis.
When a compound of formula (I) is obtained as a mixture of enantiomers, these may be separated by conventional methods such as crystallisation in the presence of a resolving agent, or chromatography, for example using a chiral HPLC column.
The invention also encompasses any novel intermediates described herein, in particular those of formulae (II), (IV), (VI), (VII), (Vϋl), (IX) and (XII).
Compounds of the invention have been found to exhibit high calcium influx blocking activity, for example in neurons. As such the compounds are expected to be of use in therapy in treating conditions and diseases related to an accumulation of calcium in the brain cells of mammals, in particular humans. For example, the compounds are expected to be of use in the treatment of anoxia, ischaemia including for example stroke, migraine, visceral pain, epilepsy, traumatic head or spinal injury, AIDS -related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal. The invention also provides a method of treatment of conditions or diseases related to (e.g. caused or exacerbated by) the accumulation of calcium in the brain cells of mammals which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) as hereinbefore defined or a pharmaceutically acceptable salt thereof.
Thus for example, the present invention provides a method of treatment of anoxia, ischaemia including for example stroke, migraine, visceral pain, epilepsy, traumatic head or spinal injury, AIDS -related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal, which comprises administering to a subject in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
For use in medicine, the compounds of the present invention are usually administered in a standard pharmaceutical composition. The present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound of formula (I) as hereinbefore defined or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
The compounds of the invention may be administered by any convenient method for example by oral, parenteral, buccal, rectal or transdermal administration and the pharmaceuucal compositions adapted accordingly. Parenteral administration is generally preferred. The compounds of formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
Compounds of the invention may also be administered parenterally, by bolus injection or continuous infusion. Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
Both liquid and solid compositions may contain other excipients known in the pharmaceutical art, such as a cyclodextrin or a solubilising agent e.g. cremophore. Preferably the composition is in unit dose form such as a tablet, capsule or ampoule.
Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 60 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base. The daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, eg. 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of between 0J mg and 100 mg, preferably between 0J mg and 60 mg, eg. 1 to 40 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Alternatively the compounds of the invention may be administered by continuous intravenous infusion, preferably at a dose of up to 400 mg per day. Thus the total daily dosage by oral administration could be in the range 1 to 2000 mg and the total daily dosage by parenteral administration could be in the range OJ to 400 mg. The compounds may be administered for a period of continuous therapy, for example for a week or more.
If desired a compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered in combination or concurrently with one or more other therapeutic agents, for example a thrombolytic agent such as anistreplase, streptokinase or a tissue plasminogen activator; an excitatory amino acid antagonist such as an NMDA antagonists; a free radical inhibitor; or a calpain inhibitor.
BIOLOGICAL DATA In Vitro
Ca*^+ Current Measurement
Cell preparations
Sensory neurons from dorsal root ganglia were dissociated from 1 day old rat pups (Forda et al, Developmental Brain Research, 22 (1985), 55-65). Cells were plated out onto glass coverslips and used within 3 days to permit effective voltage clamp of Ca2+ currents. Superior cervical ganglion neurons were isolated and cultured following a method modified from Marrion et al, Neurosci. Lett., 77, 55-60 (1987). Cells were plated onto laminin coated plastic tissue culture dishes and incubated at 37°C until just prior to recording. Electrophysiological recordings were performed from 2 to 9 days after dissociation.
Solutions
The pipette (internal solution) contained in mM: CsCl, 130; HEPES, 10; EGTA, 10; MgCl2, 4; ATP, 2; buffered to pH 7.2 with CsOH. Cells were bathed in a normal Tyrodes solution before establishment of whole cell recording when the bathing solution was changed to one allowing isolation of Ca2+ currents. The external solution for recording Ca2+ channel currents contained in mM: BaCl2, 10; TEA-C1, 130; glucose, 10; HEPES, 10; MgCl2, 1; buffered to pH 7.3 with TEA-OH. Barium was used as the charge carrier as this assists in current isolation and calcium dependent inactivation of current is avoided. Compounds were dissolved in DMSO to make a 20 mM stock solution. At the drug concentration used the vehicle (0.1%) had no significant effect on Ca + currents. All experiments were performed at 21 to 24°C. Whole cell currents were recorded using List EPC-7 amplifiers and stored, digitised for later analysis using PC based software similar to that described previously (Benham & Tsien, Journal of Physiology (1988), 404, 767-784). Ca2+ currents
Peak voltage gated Ca2+ channel currents of up to 10 nA from dorsal root ganglion neurons were recorded using 10 mM Ba2+ as charge carrier. Currents were evoked from a holding potential of -80 mV to a test potential of 0 or +10 mV every 15 seconds. This test potential was at the peak of the current voltage relationship and assessing block at this point reduced any errors due to drifting holding potential. Some cells showed slow rundown of current as is commonly seen when recording Ca2+ currents. The rundown rate was measured in control conditions and extrapolated through the time of drug application to derive a rundown corrected control value.
Dorsal Root Ganglion Cells
Block by 20 μM drug was assessed 3 minutes after drug application.
In this test compounds of Examples 1 and 2 gave percentage inhibition of plateau Ca2+ current in the range 91-98%.
Superior Cervical Ganglion Cells
Once a constant calcium current had been recorded for 4 successive pulses (1 minute) 10 μM Nimodipine, a dihydropyridine, was applied to the cell to block L type calcium current. After three minutes 5μM drug was coapplied with lOμM Nimodipine for three minutes. Such drug application tested the block of the remaining, predominantly N type, calcium current
In this test compounds of Examples 1, 3. 4 and 5 gave percentage inhibition of plateau Ca2+ current in the range 68-84%.
Pharmaceutical Formulations
The following represent typical pharmaceutical formulations according to the present invention, which may be prepared using standard methods.
IV Infusion
Compound of formula (I) 1-40 mg
Buffer to pH ca 7
Solvent/complexing to 100 ml
Bolus Injection
Compound of formula (I) 1-40 mg
Buffer to pH ca 7
Co-Solvent to 5 ml
Buffer : Suitable buffers include citrate, phosphate, sodium hydroxide/hydrochloric acid.
Solvent : Typically water but may also include cyclodextrins (1-100 mg) and co-solvents such as propylene glycol, polyethylene glycol and alcohol.
Tablet
Compound 1 - 40 mg
Diluent/Filler * 50 - 250 mg Binder 5 - 25 mg
Disentegrant * 5 - 50 mg
Lubricant 1 - 5 mg
Cyclodextrin 1 - 100 mg
* may also include cyclodextrins
Diluent : e.g. Microcrystalline cellulose, lactose, starch Binder : e.g. Polyvinylpyrrolidone, hydroxypropymethylcellulose
Disintegrant : e.g. Sodium starch glycollate, crospovidone Lubricant : e.g. Magnesium stearate, sodium stearyl fumarate. Oral Suspension
Compound - 1 - 40 mg
Suspending Agent OJ - 10 mg
Diluent 20 - 60 mg Preservative 0.01 - 1.0 mg
Buffer to pH ca 5 - 8
Co-solvent 0 - 40 mg
Flavour 0.01 - 1.0 mg
Colourant 0.001 - 0J mg
Suspending agent :e.g. Xanthan gum, microcrystalline cellulose
Diluent : e.g. sorbitol solution, typically water
Preservative : e.g. sodium benzoate
Buffer : e.g. citrate Co-solvent : e.g. alcohol, propylene glycol, polyethylene glycol, cyclodextrin
The invention is further illustrated by the following non-limiting examples:
Preparation 1 N-[3-(4-Benzyloxyphenoxy)-propyl]phthalimide A solution of 4-(3-hydroxypropyl)phthalimide (4.08g), 4-benzyloxyphenol (4.40g), triphenylphosphine (5.24g) in dichloromethane (80ml) was treated with diethyl azodicarboxylate (3.2ml). The resulting solution was stirred at room temperature for 16 hours, the solvent removed and the residue chromatographed on silica gel eluted with methanol dichloromethane. Recrystallisation from toluene/hexane gave the title compound (6.45g), m.p. 145 - 146°C. Found: C, 74.16; H, 5.45; N, 3.85%. (C24H21NO4) requires: C, 74.40; H, 5.46; N, 3.62%
Preparation 2 3-(4-Benzyloxyphenoxy)propylamine
A mixture of N-[3-(4-benzyloxyphenoxy)propyl]phthalimide (5.2g), hydrazine hydrate (5.2g) and ethanol (500ml) was heated at reflux until all the solid had dissolved and heating continued for a further 30 minutes. The cooled mixture was filtered and the filtrate was evaporated. The residue was dissolved in hot ethanol, treated with cone hydrochloric acid and allowed to cool. The precipitate was collected and chromatographed on silica gel eluted with methanol/ dichloromethane/ammonia to give the title compound which was used without further purification.
Preparation 3 3-(4-Benzyloxyphenoxy)propan- l-ol
A mixture of 4-benzyloxyphenol (2.0g), 80% sodium hydride (0.30g), 3-bromopropan-l- ol (1.39g) and dimethylformamide (30ml) was stirred under nitrogen at 60°C for 4 hours. The mixture was treated with water and extracted with ether. The ether layer was separated, washed with brine, dried over sodium sulphate and the solvent was removed. The residue was triturated with water, filtered and dried under vacuum over phosphorous pentoxide to give the title compound which was used without further purification. Preparation 4
N-[3-(3,4-Dichlorophenoxy)propyI]phthalimide
Using the conditions of Preparation 1, substituting 3,4-dichlorophenol (16.3g) for 4- benzyloxyphenol and using corresponding molar amounts of the other reagents gave the title compound as a sticky white solid (30g) which was used without further purification.
Preparation 5
3-(3,4-Dichlorophenoxy)propylamine
The product from Preparation 4 (30g), hydrazine hydrate (30ml) and ethanol (750ml) were heated at reflux until all the solid had dissolved and heating was continued for a further 30 minutes. The cooled mixture was filtered and the filtrate was evaporated. The residue was dissolved in ether, washed with dilute sodium hydroxide solution and brine, dried over sodium sulphate and the solvent removed to give an oil which was distilled in a Kugelrohr apparatus to give the title compound as a colourless oil, b.p. 160-170°C (oven temperature) @ 0.05mmHg.
Preparation 6
N-[3-(4-Benzylphenoxy)propyl]phthalimide
Using the conditions of Preparation 1 substituting 4-hydroxydiphenylmethane (4Jg) for 4- benzyloxyphenol and using corresponding molar amounts of the other reagents gave the title compound as a white solid (7.89g) which was used without further purification.
Preparation 7 3-(4-Benzylphenoxy)propylamine hydrochloride The product from Preparation 6 (7.5g), hydrazine hydrate (7.5ml) and ethanol (250ml) were heated at reflux until all the solid had dissolved and heating was continued for a further 30 minutes. The cooled mixture was filtered and the filtrate was evaporated. The residue was dissolved in hot ethanol (150ml) and treated with concentrated hydrochloric acid (10ml). The resulting solution was allowed to cool and the precipitate was collected to give the title compound as a white solid which was used without further purification.
Preparation 8
4-(3-Bromopropyloxy)-4'-fluorobenzophenone
A mixture of 4-fluoro-4'-hydroxybenzophenone (lO.Og), 1,3-dibrompropane (14.0g), benzyltrimethylammonium chloride (0.4g), sodium hydroxide (2Jg), water (200ml) and dichloromethane (40ml) was refluxed for 48 hours. The cooled mixture was extracted with dichloromethane. The dichloromethane extracts were washed with brine, dried over sodium sulphate and the solvent was removed. Chromato graphy on silica gel eluted with dichloromethane gave the title compound, (2.28g) as an oil which was used without further purification.
Example 1
N-[3-(4-Ben_yloxyphenoxy)propyl]-N-[3-(l-piperidino)propyl]amine dihydrochloride
A mixture of 3-(4-benzyloxyphenoxy)propylamine (1.92g), 80% sodium hydride (0.46g), l-(3-chloropropyl)piperidine hydrochloride (1.5 lg) and dimethylformamide (30ml) was stirred under nitrogen at 60°C for 16 hours. The mixture was treated with water and extracted with ether. The ether layer was separated, treated with dilute hydrochloric acid and the resulting solid was collected, chromatographed on silica gel eluted with ethyl acetate/methanol and recrystallised from n-propanol to give the title compound, (0.445g) m.p. 236 - 242°C.
Found: C, 61.42; H, 7.55; N, 5.90; Cl, 15.07% (C24H34N2O2.2HCI.O.75H2O) requires: C, 61.46; H, 8.06; N, 5.97; Cl, 15.12%
Example 2 l-{3-[3-(4-Benzyloxyphenoxy)propyloxy]propyl}piperidine hydrochloride
A mixture of 3-(4-benzyloxyphenoxy)propan-l-ol (1.85g), 80% sodium hydride (0.72g), l-(3-chloropropyl)piperidine hydrochloride (1.58g) and dimethylformamide (30ml) was stirred under nitrogen at 60°C for 48 hours. The mixture was treated with water and extracted with ether. The ether layer was separated, washed with brine, dried over sodium sulphate and the solvent was removed. The residue was dissolved in dichloromethane and treated with dilute hydrochloric acid. The organic phase was separated, washed with water, dried over sodium sulphate and evaporated. The residue was purified by HPLC using a 'Bondapack' silica column eluted with 9:1 methanol/ammonium hydroxide. Recrystallisation from ethyl acetate gave the title compound, (0.217g) m.p. 136 - 137°C. Found: C, 68.62; H, 7.99; N, 3.42%
(C24H33NO3.HCI) requires: C, 68.64; H, 8J6; N, 3.33%
Example 3
N-[3-(3,4-Dichlorophenoxy)propyl]-N-[3-(l-piperidino)propyl]amine dihydrochloride A mixture of 3-(3,4-dichlorphenoxy)propylamine (2.2g), 80% sodium hydride (0.6g), 1- (3-chloropropyl)piperidine hydrochloride (1.98g) and dimethylformamide (30ml) was stirred under nitrogen at 60°C for 36 hours. The mixture was treated with water and extracted with ether. The ether layer was washed with dilute sodium hydroxide solution and brine, dried over sodium sulphate and the solvent removed. The resulting oil was dissolved in ether, treated with ethereal hydrogen chloride, the precipitate was collected and recrystallised from ethanol to give the title compound, (0.683g) m.p. 235 - 237°C. Found: C, 48.07; H, 6.56; N, 6.60% (Cι7H26Cl2N2O.2HC1.0.5H2θ) requires: C, 47.90; H, 6.62; N, 6.51%
Example 4 N-[3-( 4-Benzylphenoxy)propyl]-N-[3-(l-piperidino)propyl]a_nine dihydrochloride
A mixture of 3-(4-benzylphenoxy)propylamine hydrochloride (1.25g), 80% sodium hydride (0.405g), l-(3-chloropropyl)piperidine hydrochloride (0.98g) and dimethylformamide (15ml) was stirred under argon at 60°C for 45 hours. The solvent was removed and the residue was dissolved in chloroform and then washed with dilute sodium hydroxide solution and brine, dried over sodium sulphate and the solvent removed. The resulting oil was dissolved in ether, treated with ethereal hydrogen chloride, the precipitate was collected and recrystallised from ethanol to give the title compound, (0.242g) m.p. 223 - 225°C. Found: C, 64.71; H, 8.05; N, 6.37; Cl, 16.13% (C24H34N2O.2HCI.O.33H2O) requires: C, 64.71; H, 8.26; N, 6.26; Cl, 15.92%
Example 5
N-{3-[4-(4-Fluorobenzoyl)phenoxy]propyl}-N-[3-(l-piperidino)propyl]amine dihydrochloride A mixture 1-piperidinopropylamine (0.426g), 80% sodium hydride (0.072g), and dimethylformamide (10ml) was stirred under argon at 40°C for 0.5hours. The resulting solution was treated with 4-(3-bromopropyloxy)-4'-fluorobenzophenone (l.Og) and then stirred under argon at 60°C for 18 hours. The solvent was removed and the residue was disolved in chloroform and then washed with dilute sodium hydroxide solution and brine, dried over sodium sulphate and the solvent removed. The resulting oil was dissolved in ether, treated with ethereal hydrogen chloride, and the precipitate collected. Chromatography on silica gel eluted with 10% methanol in chloroform and crystallisation under ether gave the title compound as a cream-coloured solid, (0.35g), m.p. 205 - 207°C. Found: C, 58.95; H, 6.90; N, 5.72%
(C24H31FN2O2.2HCI.H2O) requires: C, 58.89; H, 7.20; N, 5.72%

Claims

Claims
1. A compound of formula (I) :
Formula (I) wherein
R1 and R2 each independently represent: hydrogen, Ci.galkyl, C3_g_y_loalkyl, C3.gcycloalkylC galkyl, arylCι_4_lkyl, C2-6nydroxyalkyl or R-^R'*1NC2-6 lkyl (where R- and R4 independently represent H or C galkyl) or NR--R2 represents a saturated heterocyclic ring containing 4 to 9 ring members, one of which may optionally be a further heteroatom selected from O, S or NR-\ (where R5 is H, Chalky! or arylCι_4_lkyl), which ring may optionally be substituted by one or two substituents selected from Ci.galkyl and Ci.galkoxy; X represents O, S or NR^ (where R6 is hydrogen, C galkyl or arylC galkyl); Y represents O, S, C=O or a bond; n is 2 to 5; m is 1 to 5 (providing that when m is 1, Y represents a bond); and Ar represents phenyl optionally substituted by 1-3 substituents selected from halo, Ci.galkyl, Ci .galkoxy, Cι_2alkylenedioxy e.g. methylenedioxy, trifluoromethyl, trifluoromethyloxy, or by a group Ph(Alk-*)pA(Alk2)q- where Ph is optionally substituted phenyl, A is a bond, O, S, -C=O or CH=CH, Alk1 and Alk2 independently represent Cι_4alkyl which may be straight or branched and p and q are independently 0 or 1, provided that the length of -(Alk1)pA(Alk2)q-does not exceed 5 atoms, or Ar is an optionally substituted tricyclic heteroaryl group:
in which Y1 is Y (CH2)r where r is 0 or 1 and Y2 is O, S or NR? where R**7 is hydrogen or Cι_4alkyl, Z is (CH2)S or -CH=CH-, s is 0, 1 or 2 or Ar is the corresponding tricyclic dehydro ring system; or a pharmaceutically acceptable salt thereof for use as a therapeutic agent.
2. Use of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a condition where a calcium antagonist is required.
3. A method of treatment of a condition or disease related to the accumulation of calcium in the brain cells of mammal which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) as hereinbefore defined or a pharmaceutically acceptable salt thereof.
4. A compound of formula (IA):
1 a
R
N-(CH2)nXa .2)mYaAra R2a
Formula (IA) wherein n and m are as defined for formula (I) and R a, R2a, Xa, Ya and Ara are as defined for R1, R2, X, Y, and Ar; with the proviso that when Xa represents O, Ya represents O or a bond, and Rla and R2a represent Ci.galkyl or NRlaR a represents pyrrolidino, piperidino or morpholino then Ar*-* does not represent phenyl substituted by halogen, alkyl or alkoxy; or a salt thereof.
5. A compound according to claim 4 wherein n and m independently represent from 2 to 4.
6. A compound according to claim 4 or claim 5 wherein Ya represents oxygen.
7. A compound according to any of claims 4 to 6 wherein Xa represents oxygen or NR^.
8. A compound according to any of claims 4 to 7 wherein Ara represents phenyl substituted by a group Ph(Alk )pA(Alk2)q-.
9. A compound of formula (IA) selected from : N-[3-(4-benzyloxyphenoxy)propyl]-N-[3-(l-piperidino)propyl]amine; 1- { 3-[3-(4-benzyloxyphenoxy)propyloxy]propyl } piperidine, N-[3-(3,4-dichlorophenoxy)propyl]-N-[3-(l-piperidino)propyl]amine, N-[3-(4-benzylphenoxy)propyl]-N-[3-(l-piperidino)propyl]amine, N-{3-[4-(4-fluorobenzoyl)phenoxy]propyl}-N-[3-(l-piperidino)propyl]amine, or a pharmaceutically acceptable salt thereof.
10. A process for the preparation of a novel compound of formula (I) or a salt thereof which comprises: (a) to prepare a compound wherein X represents O, S or NR*-" or Y represents O or S, reaction of a compound of formula (II):
1
R
\
N(CH2)n[X(CH2)m]xL
R2
Formula (II) in which R , R2, X, n and m are as defined in formula (I), x is zero or 1 and L is a group displaceable with a nucleophile with a compound of formula (III) :
H[X(CH2)m]yYAr
Formula (HI) in which Ar, X and m are as defined in formula (I), Y represents O or S and y represents zero or 1 such that the sum of x + y = 1; (b) reaction of a compound of formula (IV) :
L2(CH2)nX(CH2)mYAr Formula (IV) in which Ar, X, Y, m and n are as defined for formula (I),and L2 is a leaving group, with a compound of formula (V) : R1 R2NH
Formula (V) in which R1 and R2 are as defined in formula (I); or
(c) reduction of an amide of formula (VI), (VII), (Vϋl) or (DC) :
Formula (VI)
Formula (VII)
Formula (VHI)
Formula (IX)
O wherein R1, R2, X, Y, Ar, n and m are as defined above and R c is a group reducible to R1 d) Reductive amination of an aldehyde of formula (X) :
OHC-(CH2)n-lX(CH2)mYAr
Formula (X) wherein Ar, X, Y, n and m are as hereinbefore defined, in the presence of a compound of formula (V) as defined above. e) To prepare a compound wherein Ar represents phenyl substituted by Ph(Alk )pO-, alkylation of a compound of formula (XI) :
Formula (XI) wherein R1, R2, X, Y, n and m are as hereinbefore defined; with an alkylating agent of formula (XII) :
PhCAlk^pL1
Formula (XII) wherein Ph, Alk1, p and L1 are as hereinbefore defined. f) To prepare a compound where R^-^N- represents an optionally substituted piperidine ring, reduction of a pyridine derivative of formula (XIII) :
A_
Formula (XIII) wherein Ar, X, Y, n and m are as hereinbefore defined, R^ represents hydrogen or an optional substituent as hereinbefore defined and A" is a counter anion; g) to prepare a compound wherein X represents O, S or NR6 or Y represents O or S, reaction of a compound of formula (XIV) :
1
R
\ (CH2)nXl(CH2)mY]xH
R2/
Formula (XIV) wherein R , R2, X, n and m are as defined in formual (I), Y is O or S and x is zero or 1; with a compound of formula (XV) : L [(CH2)mY]yAr
Formula (XV) wherein Ar, m and L2 are as hereinbefore defined, Y is O or S and y is zero or 1 such that the sum of x + y = 1; h) Interconversion of one compound of formula (I) to a different compound of formula (I) e.g.
(i) reduction of a compound wherein A represents CH=CH to a compound wherein
A represents -CH2CH2-; (ii) reduction of a compound wherein A and/or Y represent C=O to a compound wherein A and/or Y represent -CH2-; followed if desired by salt formation.
11. A pharmaceutical composition comprising a compound of formula (I) or (IA) as hereinbefore defined or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient
EP94929536A 1993-10-22 1994-10-11 Amine derivatives as calcium channel antagonists Withdrawn EP0724578A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939321812A GB9321812D0 (en) 1993-10-22 1993-10-22 Pharmaceuticals
GB9321812 1993-10-22
PCT/EP1994/003358 WO1995011240A1 (en) 1993-10-22 1994-10-11 Amine derivatives as calcium channel antagonists

Publications (1)

Publication Number Publication Date
EP0724578A1 true EP0724578A1 (en) 1996-08-07

Family

ID=10743964

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94929536A Withdrawn EP0724578A1 (en) 1993-10-22 1994-10-11 Amine derivatives as calcium channel antagonists

Country Status (6)

Country Link
EP (1) EP0724578A1 (en)
JP (1) JPH09504014A (en)
AU (1) AU7855394A (en)
GB (1) GB9321812D0 (en)
WO (1) WO1995011240A1 (en)
ZA (1) ZA948232B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE294778T1 (en) 1995-01-23 2005-05-15 Daiichi Suntory Pharma Co Ltd IMPROVEMENT OR CURE OF SYMPTOMS CAUSED BY ISCHEMIC DISEASES AND PHENYLPIPERIDINE COMPOUNDS USABLE THEREFOR
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6251919B1 (en) 1998-02-27 2001-06-26 Warner-Lambert Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
JP4904948B2 (en) * 2006-07-04 2012-03-28 住友化学株式会社 Method for producing intermediate alcohol compound
CA2986083A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB560568A (en) * 1910-09-26 1944-04-11 Geigy Ag J R Manufacture of basic 1 : 3-dialkoxy-propanols and 1 : 3-dialkoxy-propanones
BE588558A (en) * 1959-03-13 1960-09-12
US3239520A (en) * 1961-11-20 1966-03-08 Nl Combinatie Chem Ind N-(monocarbocyclic aryloxy-lower alkyl)-n' (diloweralkyl, or heterocyclic)-lower alkylene diamines
US4518713A (en) * 1984-04-13 1985-05-21 Hoechst-Roussel Pharmaceuticals Inc. Analgesic substituted-1-aminoalkylamino-4-aryloxypiperidines
DE3418271A1 (en) * 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach NEW BENZAZEPINE DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
DK625886A (en) * 1986-07-25 1988-01-26 Cheminova As AMINOETHERS AND THEIR USE AS FUNGICIDES
EP0491243B1 (en) * 1990-12-19 1996-05-15 Kali-Chemie Pharma GmbH Alkylaminoalkylamino and -ether compounds as well as processes and intermediates for their preparation, and medicaments containing these compounds
GB9220735D0 (en) * 1992-10-02 1992-11-18 British Tech Group Heterocyclic amines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9511240A1 *

Also Published As

Publication number Publication date
AU7855394A (en) 1995-05-08
WO1995011240A1 (en) 1995-04-27
GB9321812D0 (en) 1993-12-15
ZA948232B (en) 1996-04-22
JPH09504014A (en) 1997-04-22

Similar Documents

Publication Publication Date Title
AP279A (en) 4 substituted piperidine derivatives, processes for their preparation pharmaceutical compositions containing them and their use in therapy.
US4879300A (en) Novel piperidine derivatives
CS216544B2 (en) Method of preparation of basic ethers
EP0025111A1 (en) 3-Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them
EP0629190A1 (en) Compounds as calcium channel antagonists
US5817698A (en) Substituted cycloalkylamine derivatives and their use as calcium channel antagonists
WO1994013291A1 (en) Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives
NZ239267A (en) 3-substituted piperidine derivatives and pharmaceutical compositions
US5852019A (en) Pyrimidinylpyrazole derivatives
US4983633A (en) Amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same
EP0325406B1 (en) Diamine compounds
AU5833494A (en) Piperidine derivatives as calcium channel antagonists
WO1992022527A2 (en) 3-substituted pyrrolidine derivatives as calcium channel antagonists
WO1995011240A1 (en) Amine derivatives as calcium channel antagonists
US4994617A (en) Aminoalcohols, their preparation process and their applications, particularly in therapeutics
EP0724577A1 (en) Heterocyclic amines for treating ischaemic strokes
NZ196086A (en) 1-phenyl-2-cyclohexene-1-alkylamine derivatives and pharmaceutical compositions
WO1995024390A1 (en) Novel phenyl(-alkyl/alkoxy)-1-aminoalkyl-substituted piperidines and pyrrolidines as calcium channel antagonists
EP0230020B1 (en) 1,2,3,4,4a,9b-hexahydro-4a-aminoalkyldibenzofurans, a process for their preparation and their use as medicaments
AU3959893A (en) N-aryloxy(thio)alkyl-azacycloalkanes useful as calcium channel antagonists
US4237311A (en) 2-Methyl-1-(substituted)phenyl-2-propyl esters of 2-aminopropanoic acid
HUT72294A (en) Cyclic amine derivatives, pharmaceutical compositions containing them and process for producing thereof
EP0505481A1 (en) 2-substituted 4,5-diphenyl-imidazoles
EP0052311A1 (en) 1-((Benzoylphenyl) - lower-alkyl) piperidines and carbinol analogs and preparation thereof
GB2040936A (en) Phenylthiophenylpiperidines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960416

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980501